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treatment with decitabine and TSA increased docetaxel sensitiv-
ity in MCF-7 and MDA-MB-231 cells (P < 0.05). An array of 84 genes
identified 5 genes decreased in resistant cells whose expression
was upregulated after decitabine and TSA treatment (P < 0.05).
Western analysis confirmed expression changes in only one gene,
SERPINE1, in docetaxel-resistant cells.
Conclusions: Docetaxel resistance is associated with changes in
the DNAmethylation machinery. Inhibiting DNAmethylation and
histone deacetylation, in combination, overcomes resistance of
breast cancer cells to docetaxel. Our findings indicate that
decreased SERPINE1 expression is associated with docetaxel
resistance.
doi:10.1016/j.ejcsup.2010.06.012
O-12 TRANSLATIONAL EXPLORATION OF PIK3/Akt pathway
activation in early invasive breast cancer
Mohammed A. Aleskandarany, Emad A. Rakha, Mohammed A.
Ahmed, Des G. Powe, Ian O. Ellis, Andrew R. Green. Division of
Pathology, Nottingham University Hospitals and University of
Nottingham, Nottingham, UK
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a fre-
quently deregulated pathway in breast cancer (BC). Akt arguably
relays a plethora of extracellular signals to modulate diverse bio-
logic effects, including cell proliferation, growth, motility, and sur-
vival, downstream of PI3K activation. However, complexity and
diversity in the upstream/downstream arms of this pathway chal-
lenge considerably the clinical evolvement of effective therapies.
This study aims to study expressions of PIK3CA and phospho-
Akt1 (pAkt) in BC, with respect to proteins upstream/downstream
of Akt activation, clinicopathologic parameters, and disease out-
come. PIK3CA and pAkt (ser473) were evaluated by immunohisto-
chemistry on tissue microarrays containing 1202 early invasive
BC with long term follow-up.
In this study, pAktoverexpressionwasassociatedwithpatients’
age, estrogen and androgen receptors, cytokeratin (CK)18, CK19
and PTEN expression. Loss of pAkt was correlated with higher
grade, CK5/6, p53 and Ki-67 labelling index. Luminal-like tumours
displayedmore pAkt positivity than triple negative/basal-like sub-
types. However, pAkt overexpression was not associated with
breast cancer-specific (BCSS) or metastasis-free survival (MFS).
Four combinatorial phenotypes were identified based on PIK3CA
and pAkt expression, with considerable proportions being
PIK3CA/pAkt+ or PIK3CA+/pAkt. These phenotypes were signifi-
cantly associated with BCSS (p = 0.001) and MFS (p = 0.002).
Although pAKT is an oncogene that correlated with poor prog-
nostic variables, itwasnot aprognosticmarker. Combinatorial phe-
notypic groups of PIK3CA/pAkt denoted, at translational level,
functional complexity within the upstream and downstream net-
workofAktactivationwithsignificant impactonpatients’ outcome.
Thesefindingsmayhelpdevelopingadequate therapeutic regimens
against specific components of this key signalling pathway.
doi:10.1016/j.ejcsup.2010.06.013
O-13 D-gLUCURONYL C5-EPIMERASE INHIBITS BREAST CANCER
CELLS PROLIFERATION THROUGH THE TUMOUR SUPPRESSOR
GENES ACTIVATION
T.Y. Prudnikova a, N.V. Domanitskaya a, L.A. Mostovich a, T.V.
Pavlova b, V.I. Kashuba b,c, E.R. Zabarovsky b,d, E.V.
Grigorieva a,b. a Institute of Molecular Biology and Biophysics,
Novosibirsk, Russia. bMTC, Karolinska Institute, Stockholm,
Sweden. c Institute of Molecular Biology and Genetics, Kiev,
Ukraine. dEngelhard Institute of Molecular Biology, Moscow, Russia
D-Glucuronyl C5-epimerase (GLCE) is one of the key enzymes
of the biosynthesis of heparan sulphate proteoglycans. Down-
regulation of GLCE expression in human breast tumours and can-
cer cell lines suggested a possible involvement of the gene in
breast carcinogenesis. To test the hypothesis, we ectopically
expressed GLCE in breast cancer cells MCF7 and showed that
re-expression of D-glucuronyl C5-epimerase significantly inhibited
proliferative activity of MCF7 cells according to CyQUANT NF Cell
Proliferation Assay and did not affect the viability of the cells in
Colony Formation Test. The antimitotic effect of D-glucuronyl C5-
epimerase in human breast cancer cells probably is realised via
the activation of tumour suppressor genes SYK (+8.1-fold), BRCA1
(+3.5-fold), p53 (+3.3-fold) and E2F1 (+3.00-fold) and change of a
balance of pro- and anti-apoptotic factors BCL2 (+4.2-fold), NFKB1
(+2.6-fold) and TNF (+4.6-fold) (PathFinder RT Profiler PCR Array).
Also, GLCE re-expression in MCF7 cells considerably changed
expression of some genes involved in angiogenesis (IL8, IFNB1,
TNF and TGFB1) and invasion/metastasis (SYK, NME1, S100A4)
suggesting a possible antimetastatic effect of GLCE in vivo.
In summary, the ability of the D-glucuronyl C5-epimerase to sup-
press proliferation of breast cancer cells through the affecting dif-
ferent key genes involved in cell cycle regulation, angiogenesis
and invasion/metastasis molecular pathways supposes the gene
as a new potential candidate for diagnosis and treatment of
breast cancer.
doi:10.1016/j.ejcsup.2010.06.014
O-14 EXPRESSION AND ACTIVATION OF Akt AND NFkB IN
BREAST CANCER PATIENTS
J. Edwards, C. Tannahill, C. Obondo, B. Elsberger, E. Mallon, C.
Wilson, J. Doughty. Western Infirmary/University of Glasgow,
Glasgow, UK
Background: It is postulated that Akt activates the Nf-kB
pathway to promote tumour growth and survival in breast cancer
cells.
Material and methods: Tissue microarray technology was
employed to analyse tissue from 426 breast cancer patients.
Immunohistochemistry was performed using antibodies for pAkt
(phosphorylated at serine 473), NF- kB and pNFkappaB (phosphor-
ylated at serine 536). Expression was assessed using the weighted
histoscore method by two independent scorers.
Results: Median age was 62 years, median tumour size was
20 mm, 48% were pathologically graded G2 and 31% G3 and 48%
were lymph node positive. Ninety-eight patients had unilateral
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recurrence and 15 patients had bilateral recurrence, median time
to recurrence was 3.2 years and median follow-up time was
6.2 years. A weak correlation was observed between cytoplasmic
pAkt and cytoplasmic pNF-kB (cc 0.166, P = 0.001). Cytoplasmic
pAkt expressionwas associatedwith decreased time to recurrence
(p = 0.025) and was significantly higher in ER negative tumours
compared to ER positive (p = 0.004). When cohort was split by PR
status, the associationwith decreased time to recurrence and cyto-
plasmicpAktwaspotentiated (p = 0.008).CytoplasmicpAktexpres-
sioncorrelatedsignificantlywithnuclearpAktexpression (cc0.696,
p < 0.001). Nuclear pAkt expression was also associated with
decreased time to recurrence (p = 0.043). In addition the observa-
tion with nuclear pAkt was potentiated in ER negative tumours
(p = 0.037) andPRnegative tumours (p = 0.002). No significant corre-
lation with time to recurrence was observed for NF-kB or pNF-kB.
Conclusion: In the current cohort pAkt expression was associ-
ated with recurrence, however this was independent of the NF-
kB cascade.
doi:10.1016/j.ejcsup.2010.06.015
O-15 UPREGULATION OF THE ESTROGEN PATHWAY IN ENDO-
CRINE SENSITIVE BREAST CANCER CELLS WITH HERCEPTIN
TREATMENT
J.G. Solon, D. Collins, M. McIlroy, A.D.K. Hill, L. Young. Endocrine
Oncology Research Group, Royal College of Surgeons in Ireland, Ireland
Breast cancer is the leading cause of cancer-related deaths in
women in Ireland. Receptor crosstalk has been implicated in the
development of resistance to therapies and cancer relapse. We
have previously shown that treatment of endocrine insensitive
or independent breast cancer cells with herceptin repressed tran-
scriptional activity of the oncogene c-Myc through SMRT activity.
However, endocrine sensitive breast cancer cells with low levels
of HER2 receptor showed hyperactivation of the estrogen/steroid
pathway through recruitment of the cointegrator protein CBP.
The aim of this study was to demonstrate the activation of the
steroid pathway in endocrine sensitive breast cancer cells treated
with herceptin using the classical ER target gene pS2 as a marker
of activity.
MCF-7cells (highER, lowHER2, endocrinedependent) andLCC-1
cells (highER,highHER2, endocrine independent)were treatedwith
estradiol (E2), tamoxifen and herceptin. Semi-quantitative RT-PCR
and qRT- PCR was performed to quantify pS2 mRNA levels. The
impact of treatments on pS2 promoter activity was then assessed.
Cells were transfected with the expression vector pSG5- ERa and
the luciferse reporter plasmid pGL3-pS2 promoter and the level of
transcriptional activity recorded. Increases in pS2 mRNA were
found inMCF-7 cells treatedwithherceptinbutnot LCC-1 cells. This
was replicated at a transcriptional level through luciferase assay.
We have shown that at mRNA and transcriptional levels treat-
ment of MCF-7 cells with herceptin results in upregulation of the
steroid pathway. We are currently conducting further molecular
studies to further elucidate the signalling pathways involved.
doi:10.1016/j.ejcsup.2010.06.016
O-16 JAMA-A: A HOPE FOR BREAST CANCER THERAPY?
Gozie Offiah. Department of Surgery, Royal College of Surgeons,
Ireland
Background: Breast cancer is a very prevalent disease with
most cancers originating in the milk ducts, composed of a layer
of polarized epithelial cells. Loss of polarity is a hallmark of
many cancers including breast. We recently showed a novel
correlation between over-expression of the cell adhesion pro-
tein JAM-A and poor prognosis in invasive breast cancer
patients.1
Aim: To determine whether JAM-A regulates proliferation and
polarity in breast cancer cells in a manner explaining its associa-
tion with aggressive cancer phenotypes.
Materials and methods: Proliferation assays were carried out
using the isogenic breast cancer cell line series HMT-3522, of S1
(normal) and T42 (invasive) cells in the presence of an inhibitory
JAM-A antibody. Both cell types were grown in a 3-dimensional
(3D) extracellular matrix culture model. Cultures were exposed
to inhibitory JAM-A antibody to determine the consequences
of antagonising JAM-A function for 3D polarization and
differentiation.
Results: We observed significant anti-proliferative effects in
both S1 and T42 cells exposed to JAM-A inhibitory antibody over
time. Both S1 and T42 cells treated with JAM-A inhibitory anti-
body showed significant reductions in 3D spheroidal diameter rel-
ative to IgG-treated cells (p < 0.05), correlating with observed anti-
proliferative effect. Furthermore, invasive T4-2 cells in 3D culture
treated with JAM-A inhibitory antibody exhibited a partial nor-
malization of phenotype.
Conclusions: Our results indicate that JAM-A inhibition
decreases proliferation and promotes polarisation. Therefore,
we speculate that pharmacological antagonism of JAM-A in
breast cancer patients may offer a novel therapeutic opportunity.
Reference:
1. McSherry EA, McGee SF, Jirstrom K, Doyle EM, Brennan DJ,
Landberg G, et al. JAM-A expression positively correlates with
poor prognosis in breast cancer patients. Int J Cancer
2009;125(6):1343–51.
doi:10.1016/j.ejcsup.2010.06.017
O-17 BORDERLINE HER2 PROTEIN POSITIVE BREAST CANCERS
HAVE SIMILAR PATIENT OUTCOME REGARDLESS OF HER2 GENE
AMPLIFICATION STATUS
F.F.T. Barros, M. Aleskandarany, E. Rakha, S.L. Watts, D.G. Powe,
I.O. Ellis, A.R. Green. Division of Pathology, Nottingham University
Hospitals and University of Nottingham, Nottingham, UK
HER2 plays an important role in breast cancer progression and
provides predictive and prognostic information. However, prog-
nostic information provided by IHC expression categories and
prognostic value added by using in situ hybridisation (ISH) in bor-
derline cases remains unclear.
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